GSK vs NEM
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 17, 2026
GSK
NEM
Investment Advisor Scores
NEM
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | NEM | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 21.0526 | 12.9366 | NEM |
| PEG Ratio | 105.1841 | 2.7807 | NEM |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 5.3% | 15.1% | NEM |
| Earnings Growth | -69.5% | 11.4% | NEM |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 42.4/100 | 35.9/100 | GSK |
| Profit Margin | 14.5% | 33.4% | NEM |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | SELL | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
NeutralMixed signals - no dominant trend phase, RSI 49
NEM
NeutralMixed signals - no dominant trend phase, RSI 64
Fundamentals Snapshot
| Metric | GSK | NEM |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 10.0 | 11.1 |
| Trailing P/E | 15.6 | 15.2 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.2% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.3% | 0.5% |
| EPS | 3.23 | 7.93 |
| Dividend Yield | 0.04% | 0.01% |